Pancreatic Cancer Research

ResearcherArmy Medical UniversityActive in the last 2 years

Huaizhi Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5421-5176; OpenAlex author ID A5101919706. Sources: OpenAlex.

Their work

Papers
51 (first author 0, last author 29)
Trials
0
Grants
0
Labs led
3
Collaborators
96
Papers, trials and grants by year

2013: 2 papers · 2014: 4 papers · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 6 papers · 2020: 10 papers · 2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 4 papers · 2025: 5 papers · 2026: 1 paper

Papers 50 of 51

  1. Tumor-derived CDHR2-enriched extracellular vesicles engage ANPEP on liver sinusoidal endothelial cells to facilitate transendothelial migration in PDAC. Co-author DOI 10.1016/j.canlet.2026.218774↗
  2. Disulfidptosis: a novel gene-based signature predicts prognosis and immunotherapy efficacy of pancreatic adenocarcinoma. Last author DOI 10.1007/s12672-025-02053-w↗
  3. The role of the aging process and related factor EMP1 in promoting progression of resectable pancreatic cancer. Last author DOI 10.1016/j.gendis.2024.101490↗
  4. Increased PRIM2 Expression Associated With Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002387↗
  5. A novel protein cPFKFB4 encoded by hsa_circ_0065394 strengthens PKM2-mediated glucose metabolic reprogramming to facilitate pancreatic cancer progression under… Last author DOI 10.1186/s12943-025-02500-w↗
  6. Circular RNA in Pancreatic Cancer: Biogenesis, Mechanism, Function and Clinical Application. Last author DOI 10.7150/ijms.107773↗
  7. PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B. Last author DOI 10.1007/s12032-024-02554-8↗
  8. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance. Last author DOI 10.1016/j.drup.2023.101027↗
  9. Identifying suitable candidates for pancreaticoduodenectomy with extended lymphadenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2024.07.405↗
  10. Deciphering the pancreatic cancer microbiome in Mainland China: Impact of Exiguobacterium/Bacillus ratio on tumor progression and prognostic significance. Co-author DOI 10.1016/j.phrs.2024.107197↗
  11. CircPTPRA promotes the progression of pancreatic ductal adenocarcinoma via the miR-140-5p/LMNB1 axis. Last author DOI 10.1002/cam4.5869↗
  12. DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer. Co-author DOI 10.1038/s41388-023-02817-0↗
  13. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-022-02836-z↗
  14. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Last author DOI 10.3389/fonc.2023.1138238↗
  15. Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Last author DOI 10.3389/fonc.2023.1218781↗
  16. Development and validation of a novel ferroptosis‑related lncRNA prognostic signature for pancreatic adenocarcinoma. Co-author DOI 10.3892/mmr.2023.12943↗
  17. Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by act… Last author DOI 10.1186/s12935-022-02835-0↗
  18. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s12943-022-01587-9↗
  19. Corrigendum to "Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis" [Pharmacol. Res. 156 (J… Co-author DOI 10.1016/j.phrs.2021.105657↗
  20. TMPRSS4 Promotes Cell Proliferation and Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma by Activating ERK1/2 Signaling Pathway. Co-author DOI 10.3389/fonc.2021.628353↗
  21. N6-methyladenosine (m6A) in pancreatic cancer: Regulatory mechanisms and future direction. Co-author DOI 10.7150/ijbs.60115↗
  22. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.omtn.2019.11.010↗
  23. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Co-author DOI 10.1016/j.phrs.2020.104805↗
  24. Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation. Last author DOI 10.1016/j.ygeno.2020.11.010↗
  25. The lncRNA RUNX1-IT1 regulates C-FOS transcription by interacting with RUNX1 in the process of pancreatic cancer proliferation, migration and invasion. Last author DOI 10.1038/s41419-020-2617-7↗
  26. Characterization of Oral Microbiome and Exploration of Potential Biomarkers in Patients with Pancreatic Cancer. Co-author DOI 10.1155/2020/4712498↗
  27. Upregulated GDF-15 expression facilitates pancreatic ductal adenocarcinoma progression through orphan receptor GFRAL. Last author DOI 10.18632/aging.103830↗
  28. Establishing and validating a pathway prognostic signature in pancreatic cancer based on miRNA and mRNA sets using GSVA. Last author DOI 10.18632/aging.103965↗
  29. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/aging.104091↗
  30. Activating miRNA-mRNA network in gemcitabine-resistant pancreatic cancer cell associates with alteration of memory CD4+ T cells. Last author DOI 10.21037/atm.2020.03.53↗
  31. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription. Last author DOI 10.7150/thno.44278↗
  32. Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway. Co-author DOI 10.1038/s41419-019-2073-4↗
  33. Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer. Co-author DOI 10.1080/08820139.2019.1566356↗
  34. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/febs.15134↗
  35. MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation. Co-author DOI 10.3389/fonc.2019.01499↗
  36. miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. Last author PMID 31217868↗
  37. Association of radiomic imaging features and gene expression profile as prognostic factors in pancreatic ductal adenocarcinoma. Co-author PMID 31396352↗
  38. Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting PLK1 expression. Co-author DOI 10.1016/j.canlet.2018.02.014↗
  39. Retraction notice to "Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting … Co-author DOI 10.1016/j.canlet.2018.09.027↗
  40. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Progn… Last author DOI 10.1159/000495228↗
  41. microRNA based prognostic biomarkers in pancreatic Cancer. Co-author DOI 10.1186/s40364-018-0131-1↗
  42. Microarray expression profile analysis of circular RNAs in pancreatic cancer. Last author DOI 10.3892/mmr.2018.8827↗
  43. Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. Co-author DOI 10.1016/j.canlet.2017.03.014↗
  44. Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.19578↗
  45. Transcriptomic changes associated with DKK4 overexpression in pancreatic cancer cells detected by RNA-Seq. Last author DOI 10.1007/s13277-015-4379-x↗
  46. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Last author DOI 10.1016/j.canlet.2013.10.009↗
  47. Apigenin potentiates the growth inhibitory effects by IKK-β-mediated NF-κB activation in pancreatic cancer cells. Co-author DOI 10.1016/j.toxlet.2013.10.007↗
  48. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. Last author DOI 10.1097/mpa.0000000000000055↗
  49. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0091551↗
  50. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Co-author DOI 10.1186/1476-4598-12-105↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shixiang Guo · 20 shared papers, 2014–2025 · strength 2.43
  2. Jingyang Yin · 9 shared papers, 2022–2025 · strength 2.18
  3. Fuming Xie · 9 shared papers, 2020–2025 · strength 1.50
  4. Bing Ni · 12 shared papers, 2014–2023 · strength 1.36
  5. Jianyou Gu · 10 shared papers, 2019–2024 · strength 1.28
  6. Jian Li · 4 shared papers, 2017–2025 · strength 0.90
  7. Yingfang Fan · 7 shared papers, 2019–2024 · strength 0.88
  8. Xianxing Wang · 7 shared papers, 2019–2024 · strength 0.87
  9. Songsong Liu · 10 shared papers, 2017–2020 · strength 0.86
  10. Jianyou Gu · 5 shared papers, 2020–2025 · strength 0.75
  11. Wenjie Huang · 7 shared papers, 2017–2020 · strength 0.67
  12. Bojing Chi · 4 shared papers, 2022–2023 · strength 0.62
  13. Wen Fu · 4 shared papers, 2022–2023 · strength 0.62
  14. Wenhua Li · 3 shared papers, 2018–2023 · strength 0.55
  15. Hang Chen · 2 shared papers, 2025 · strength 0.50
  16. Junfeng Zhang · 4 shared papers, 2020–2024 · strength 0.49
  17. Yunchao Wang · 6 shared papers, 2017–2020 · strength 0.49
  18. Tian Tao · 4 shared papers, 2019–2022 · strength 0.48
  19. Yongkang Liu · 3 shared papers, 2018–2023 · strength 0.48
  20. Zhiping Zhao · 5 shared papers, 2017–2020 · strength 0.42
  21. Lei Cai · 2 shared papers, 2022–2025 · strength 0.37
  22. Yongsheng Ouyang · 5 shared papers, 2014–2020 · strength 0.36
  23. Xialin Luo · 2 shared papers, 2020–2021 · strength 0.35
  24. Jingjing Liu · 2 shared papers, 2020–2021 · strength 0.35
  25. Haitao Lu · 2 shared papers, 2020–2021 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.